A reportedtumor-targeted STING agonist antibody-drug conjugate (ADC) platformdemonstrated an impressive safety profile and good efficacy.22 However, this platform encounters inherent issueswith target availability and scale-up manufacturability.23 In addition, low-level STING activation in tumorscan induce immunosuppressive factors such as indoleamine-2,3-deoxygenase(IDO), causing pathogenesis.24 As tumorcells can downregulate STING,25 agonistdelivery to tumor cells can be either ineffective or counterproductivethrough this mechanism. Here, STING1 is linked to neoplasm.